摘要
目的:探讨奥氮平治疗精神分裂症的疗效与安全性。方法:对123例精神分裂症患者随机分成两组,奥氮平组61例,氯氮平组62例,于治疗前和治疗1、24、、6、8周末进行阳性与阴性症状量表(PANSS)及副反应量表(TESS)评定疗效及不良反应。结果:奥氮平与氯氮平总的疗效差异无显著性;在认知因子和阴性症状方面,以奥氮平显著较好。奥氮平主要不良反应明显低于氯氮平。结论:奥氮平是一种安全、有效的非典型抗精神病药。
Objective： To explore the efficacy and safety of olanzapine in the treatment of schizophrenia.Method： 123 cases with schizophrenia were randomly divided into olanzapine group（ n = 61） or clozapine group（ n =62）. Positive and negative symptoms scale （PANSS） and treatment emergant symptom scale （TESS） were used to measure the efficacy and safety before treatment and at the end of 1st,2nd,4th,6th and 8th week treatment respectively. Results：There were no significant differences in effectiveness between two groups. However, significant differences were found between two groups in the reduction rates of scales about cognitive factors and negative symptoms.Conclusion：The study suggests that olanzapine is a safe and effective agent in the treatment of schizophrenia.
出处
《临床精神医学杂志》
2005年第4期224-225,共2页
Journal of Clinical Psychiatry
